{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:00:04Z","timestamp":1794589204901,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7975","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Human tripartite motif protein 5\u03b1 (TRIM5\u03b1) is a well-characterized restriction factor for some RNA viruses, including HIV\n                    <jats:sup>1\u20135<\/jats:sup>\n                    ; however, reports are limited for DNA viruses\n                    <jats:sup>6,7<\/jats:sup>\n                    . Here we demonstrate that TRIM5\u03b1 also restricts orthopoxviruses and, via its SPRY domain, binds to the orthopoxvirus capsid protein L3 to diminish virus replication and activate innate immunity. In response, several orthopoxviruses, including vaccinia, rabbitpox, cowpox, monkeypox, camelpox and variola viruses, deploy countermeasures. First, the protein C6 binds to TRIM5 via the RING domain to induce its proteasome-dependent degradation. Second, cyclophilin A (CypA) is recruited via interaction with the capsid protein L3 to virus factories and virions to antagonize TRIM5\u03b1; this interaction is prevented by cyclosporine A (CsA) and the non-immunosuppressive derivatives alisporivir and NIM811. Both the proviral effect of CypA and the antiviral effect of CsA are dependent on TRIM5\u03b1. CsA, alisporivir and NIM811 have antiviral activity against orthopoxviruses, and because these drugs target a cellular protein, CypA, the emergence of viral drug resistance is difficult. These results warrant testing of CsA derivatives against orthopoxviruses, including monkeypox and variola.\n                  <\/jats:p>","DOI":"10.1038\/s41586-023-06401-0","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T12:02:40Z","timestamp":1691582560000},"page":"873-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["TRIM5\u03b1 restricts poxviruses and is antagonized by CypA and the viral protein C6"],"prefix":"10.1038","volume":"620","author":[{"given":"Yiqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghna","family":"Sreekumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-813X","authenticated-orcid":false,"given":"Jonas D.","family":"Albarnaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-9955","authenticated-orcid":false,"given":"Geoffrey L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"6401_CR1","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1016\/j.celrep.2019.05.040","volume":"27","author":"AI Chiramel","year":"2019","unstructured":"Chiramel, A. I. et al. TRIM5\u03b1 restricts flavivirus replication by targeting the viral protease for proteasomal degradation. Cell Rep. 27, 3269\u20133283.e6 (2019).","journal-title":"Cell Rep."},{"key":"6401_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nature02343","volume":"427","author":"M Stremlau","year":"2004","unstructured":"Stremlau, M. et al. The cytoplasmic body component TRIM5\u03b1 restricts HIV-1 infection in Old World monkeys. Nature 427, 848\u2013853 (2004).","journal-title":"Nature"},{"key":"6401_CR3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41564-019-0402-0","volume":"4","author":"JM Jimenez-Guardeno","year":"2019","unstructured":"Jimenez-Guardeno, J. M., Apolonia, L., Betancor, G. & Malim, M. H. Immunoproteasome activation enables human TRIM5\u03b1 restriction of HIV-1. Nat. Microbiol. 4, 933\u2013940 (2019).","journal-title":"Nat. Microbiol."},{"key":"6401_CR4","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41564-019-0592-5","volume":"4","author":"K Kim","year":"2019","unstructured":"Kim, K. et al. Cyclophilin A protects HIV-1 from restriction by human TRIM5\u03b1. Nat. Microbiol. 4, 2044\u20132051 (2019).","journal-title":"Nat. Microbiol."},{"key":"6401_CR5","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1016\/j.celrep.2020.02.100","volume":"30","author":"A Selyutina","year":"2020","unstructured":"Selyutina, A. et al. Cyclophilin A prevents HIV-1 restriction in lymphocytes by blocking human TRIM5\u03b1 binding to the viral core. Cell Rep. 30, 3766\u20133777.e6 (2020).","journal-title":"Cell Rep."},{"key":"6401_CR6","first-page":"2129","volume":"7","author":"HH Huang","year":"2016","unstructured":"Huang, H. H. et al. TRIM5\u03b1 promotes ubiquitination of Rta from Epstein\u2013Barr virus to attenuate lytic progression. Front. Microbiol. 7, 2129 (2016).","journal-title":"Front. Microbiol."},{"key":"6401_CR7","doi-asserted-by":"publisher","unstructured":"Lin, L. T. et al. Regulation of Epstein\u2013Barr virus minor capsid protein BORF1 by TRIM5\u03b1. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms232315340 (2022).","DOI":"10.3390\/ijms232315340"},{"key":"6401_CR8","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","volume":"94","author":"GL Smith","year":"2013","unstructured":"Smith, G. L. et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J. Gen. Virol. 94, 2367\u20132392 (2013).","journal-title":"J. Gen. Virol."},{"key":"6401_CR9","unstructured":"Moss, B. & Smith, G. L. in Fields Virology: DNA Viruses Vol. 2 (eds Howley, P. M. & Knipe, D. M.) 573\u2013613 (Wolters Kluwer, 2021)."},{"key":"6401_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.celrep.2019.04.042","volume":"27","author":"L Soday","year":"2019","unstructured":"Soday, L. et al. Quantitative temporal proteomic analysis of vaccinia virus infection reveals regulation of histone deacetylases by an interferon antagonist. Cell Rep. 27, 1920\u20131933.e7 (2019).","journal-title":"Cell Rep."},{"key":"6401_CR11","doi-asserted-by":"publisher","first-page":"11997","DOI":"10.1073\/pnas.1816399116","volume":"116","author":"Y Lu","year":"2019","unstructured":"Lu, Y. et al. Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6. Proc. Natl Acad. Sci. USA 116, 11997\u201312006 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6401_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/0092-8674(95)90076-4","volume":"81","author":"JA Symons","year":"1995","unstructured":"Symons, J. A., Alcami, A. & Smith, G. L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551\u2013560 (1995).","journal-title":"Cell"},{"key":"6401_CR13","first-page":"524","volume":"167","author":"GJ Kotwal","year":"1988","unstructured":"Kotwal, G. J. & Moss, B. Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology 167, 524\u2013537 (1988).","journal-title":"Virology"},{"key":"6401_CR14","doi-asserted-by":"publisher","first-page":"e1000128","DOI":"10.1371\/journal.ppat.1000128","volume":"4","author":"SC Graham","year":"2008","unstructured":"Graham, S. C. et al. Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-\u03baB rather than apoptosis. PLoS Pathog. 4, e1000128 (2008).","journal-title":"PLoS Pathog."},{"key":"6401_CR15","doi-asserted-by":"publisher","first-page":"e1005955","DOI":"10.1371\/journal.ppat.1005955","volume":"12","author":"JH Stuart","year":"2016","unstructured":"Stuart, J. H., Sumner, R. P., Lu, Y., Snowden, J. S. & Smith, G. L. Vaccinia virus protein C6 inhibits type I IFN signalling in the nucleus and binds to the transactivation domain of STAT2. PLoS Pathog. 12, e1005955 (2016).","journal-title":"PLoS Pathog."},{"key":"6401_CR16","doi-asserted-by":"publisher","first-page":"e1002247","DOI":"10.1371\/journal.ppat.1002247","volume":"7","author":"L Unterholzner","year":"2011","unstructured":"Unterholzner, L. et al. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 7, e1002247 (2011).","journal-title":"PLoS Pathog."},{"key":"6401_CR17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.virol.2005.12.040","volume":"349","author":"F Diaz-Griffero","year":"2006","unstructured":"Diaz-Griffero, F. et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349, 300\u2013315 (2006).","journal-title":"Virology"},{"key":"6401_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.chom.2018.10.007","volume":"24","author":"AJ Fletcher","year":"2018","unstructured":"Fletcher, A. J. et al. Trivalent RING assembly on retroviral capsids activates TRIM5 ubiquitination and innate immune signaling. Cell Host Microbe 24, 761\u2013775.e6 (2018).","journal-title":"Cell Host Microbe"},{"key":"6401_CR19","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/j.1742-4658.2008.06313.x","volume":"275","author":"K Yamauchi","year":"2008","unstructured":"Yamauchi, K., Wada, K., Tanji, K., Tanaka, M. & Kamitani, T. Ubiquitination of E3 ubiquitin ligase TRIM5\u03b1 and its potential role. FEBS J. 275, 1540\u20131555 (2008).","journal-title":"FEBS J."},{"key":"6401_CR20","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1099\/vir.0.82772-0","volume":"88","author":"S Cooray","year":"2007","unstructured":"Cooray, S. et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J. Gen. Virol. 88, 1656\u20131666 (2007).","journal-title":"J. Gen. Virol."},{"key":"6401_CR21","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1371\/journal.ppat.0040022","volume":"4","author":"RA Chen","year":"2008","unstructured":"Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. Inhibition of I\u03baB kinase by vaccinia virus virulence factor B14. PLoS Pathog. 4, e22 (2008).","journal-title":"PLoS Pathog."},{"key":"6401_CR22","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1099\/vir.0.19271-0","volume":"84","author":"GC Carter","year":"2003","unstructured":"Carter, G. C. et al. Vaccinia virus cores are transported on microtubules. J. Gen. Virol. 84, 2443\u20132458 (2003).","journal-title":"J. Gen. Virol."},{"key":"6401_CR23","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.1128\/JVI.00648-11","volume":"85","author":"E Battivelli","year":"2011","unstructured":"Battivelli, E. et al. Modulation of TRIM5\u03b1 activity in human cells by alternatively spliced TRIM5 isoforms. J. Virol. 85, 7828\u20137835 (2011).","journal-title":"J. Virol."},{"key":"6401_CR24","doi-asserted-by":"publisher","first-page":"11495","DOI":"10.1128\/JVI.01548-08","volume":"82","author":"X Li","year":"2008","unstructured":"Li, X. & Sodroski, J. The TRIM5\u03b1 B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J. Virol. 82, 11495\u201311502 (2008).","journal-title":"J. Virol."},{"key":"6401_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cub.2004.12.042","volume":"15","author":"MW Yap","year":"2005","unstructured":"Yap, M. W., Nisole, S. & Stoye, J. P. A single amino acid change in the SPRY domain of human Trim5\u03b1 leads to HIV-1 restriction. Curr. Biol. 15, 73\u201378 (2005).","journal-title":"Curr. Biol."},{"key":"6401_CR26","doi-asserted-by":"publisher","first-page":"9052","DOI":"10.1128\/JVI.77.16.9052-9068.2003","volume":"77","author":"AP Castro","year":"2003","unstructured":"Castro, A. P., Carvalho, T. M., Moussatche, N. & Damaso, C. R. Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles. J. Virol. 77, 9052\u20139068 (2003).","journal-title":"J. Virol."},{"key":"6401_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01310569","volume":"134","author":"CR Damaso","year":"1994","unstructured":"Damaso, C. R. & Keller, S. J. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch. Virol. 134, 303\u2013319 (1994).","journal-title":"Arch. Virol."},{"key":"6401_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1099\/0022-1317-79-2-339","volume":"79","author":"CR Damaso","year":"1998","unstructured":"Damaso, C. R. & Moussatche, N. Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins. J. Gen. Virol. 79, 339\u2013346 (1998).","journal-title":"J. Gen. Virol."},{"key":"6401_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/357695a0","volume":"357","author":"NA Clipstone","year":"1992","unstructured":"Clipstone, N. A. & Crabtree, G. R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357, 695\u2013697 (1992).","journal-title":"Nature"},{"key":"6401_CR30","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1073\/pnas.89.9.3686","volume":"89","author":"DA Fruman","year":"1992","unstructured":"Fruman, D. A., Klee, C. B., Bierer, B. E. & Burakoff, S. J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl Acad. Sci. USA 89, 3686\u20133690 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6401_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu, J. et al. Calcineurin is a common target of cyclophilin\u2013cyclosporin A and FKBP\u2013FK506 complexes. Cell 66, 807\u2013815 (1991).","journal-title":"Cell"},{"key":"6401_CR32","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1128\/JVI.00688-06","volume":"80","author":"S Ohkura","year":"2006","unstructured":"Ohkura, S., Yap, M. W., Sheldon, T. & Stoye, J. P. All three variable regions of the TRIM5\u03b1 B30.2 domain can contribute to the specificity of retrovirus restriction. J. Virol. 80, 8554\u20138565 (2006).","journal-title":"J. Virol."},{"key":"6401_CR33","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1073\/pnas.0509996103","volume":"103","author":"M Stremlau","year":"2006","unstructured":"Stremlau, M. et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5\u03b1 restriction factor. Proc. Natl Acad. Sci. USA 103, 5514\u20135519 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6401_CR34","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1128\/JVI.79.5.3139-3145.2005","volume":"79","author":"M Stremlau","year":"2005","unstructured":"Stremlau, M., Perron, M., Welikala, S. & Sodroski, J. Species-specific variation in the B30.2(SPRY) domain of TRIM5\u03b1 determines the potency of human immunodeficiency virus restriction. J. Virol. 79, 3139\u20133145 (2005).","journal-title":"J. Virol."},{"key":"6401_CR35","doi-asserted-by":"publisher","first-page":"14719","DOI":"10.1128\/JVI.79.23.14719-14729.2005","volume":"79","author":"W Resch","year":"2005","unstructured":"Resch, W. & Moss, B. The conserved poxvirus L3 virion protein is required for transcription of vaccinia virus early genes. J. Virol. 79, 14719\u201314729 (2005).","journal-title":"J. Virol."},{"key":"6401_CR36","doi-asserted-by":"publisher","first-page":"27959","DOI":"10.1074\/jbc.M111.260406","volume":"286","author":"X Li","year":"2011","unstructured":"Li, X., Yeung, D. F., Fiegen, A. M. & Sodroski, J. Determinants of the higher order association of the restriction factor TRIM5\u03b1 and other tripartite motif (TRIM) proteins. J. Biol. Chem. 286, 27959\u201327970 (2011).","journal-title":"J. Biol. Chem."},{"key":"6401_CR37","doi-asserted-by":"publisher","unstructured":"Li, Y. L. et al. Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids. eLife https:\/\/doi.org\/10.7554\/eLife.16269 (2016).","DOI":"10.7554\/eLife.16269"},{"key":"6401_CR38","doi-asserted-by":"publisher","unstructured":"Wagner, J. M. et al. Mechanism of B-box 2 domain-mediated higher-order assembly of the retroviral restriction factor TRIM5\u03b1. eLife https:\/\/doi.org\/10.7554\/eLife.16309 (2016).","DOI":"10.7554\/eLife.16309"},{"key":"6401_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature09976","volume":"472","author":"T Pertel","year":"2011","unstructured":"Pertel, T. et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361\u2013365 (2011).","journal-title":"Nature"},{"key":"6401_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.virol.2010.09.018","volume":"409","author":"SU Tareen","year":"2011","unstructured":"Tareen, S. U. & Emerman, M. Human Trim5\u03b1 has additional activities that are uncoupled from retroviral capsid recognition. Virology 409, 113\u2013120 (2011).","journal-title":"Virology"},{"key":"6401_CR41","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/pro.5560010903","volume":"1","author":"LD Zydowsky","year":"1992","unstructured":"Zydowsky, L. D. et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1, 1092\u20131099 (1992).","journal-title":"Protein Sci."},{"key":"6401_CR42","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1016\/j.vaccine.2016.08.002","volume":"34","author":"RP Sumner","year":"2016","unstructured":"Sumner, R. P., Ren, H., Ferguson, B. J. & Smith, G. L. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Vaccine 34, 4827\u20134834 (2016).","journal-title":"Vaccine"},{"key":"6401_CR43","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1099\/vir.0.049700-0","volume":"94","author":"RP Sumner","year":"2013","unstructured":"Sumner, R. P., Ren, H. & Smith, G. L. Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J. Gen. Virol. 94, 1121\u20131126 (2013).","journal-title":"J. Gen. Virol."},{"key":"6401_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.antiviral.2011.01.003","volume":"89","author":"E Lawitz","year":"2011","unstructured":"Lawitz, E. et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res. 89, 238\u2013245 (2011).","journal-title":"Antiviral Res."},{"key":"6401_CR45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/apt.13342","volume":"42","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem, S. et al. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment. Pharmacol. Ther. 42, 829\u2013844 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"6401_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41564-021-01004-9","volume":"7","author":"JD Albarnaz","year":"2022","unstructured":"Albarnaz, J. D. et al. Molecular mimicry of NF-\u03baB by vaccinia virus protein enables selective inhibition of antiviral responses. Nat. Microbiol. 7, 154\u2013168 (2022).","journal-title":"Nat. Microbiol."},{"key":"6401_CR47","doi-asserted-by":"publisher","unstructured":"Zhang, R. Y., Pallett, M. A., French, J., Ren, H. & Smith, G. L. Vaccinia virus BTB-Kelch proteins C2 and F3 inhibit NF-\u03baB activation. J. Gen. Virol. https:\/\/doi.org\/10.1099\/jgv.0.001786 (2022).","DOI":"10.1099\/jgv.0.001786"},{"key":"6401_CR48","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1128\/jvi.65.11.5910-5920.1991","volume":"65","author":"R Blasco","year":"1991","unstructured":"Blasco, R. & Moss, B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 65, 5910\u20135920 (1991).","journal-title":"J. Virol."},{"key":"6401_CR49","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","volume":"83","author":"GL Smith","year":"2002","unstructured":"Smith, G. L., Vanderplasschen, A. & Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83, 2915\u20132931 (2002).","journal-title":"J. Gen. Virol."},{"key":"6401_CR50","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/infdis\/jis510","volume":"206","author":"ER Lederman","year":"2012","unstructured":"Lederman, E. R. et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J. Infect. Dis. 206, 1372\u20131385 (2012).","journal-title":"J. Infect. Dis."},{"key":"6401_CR51","doi-asserted-by":"publisher","unstructured":"Smith, T. G. et al. Resistance to anti-orthopoxviral drug tecovirimat (TPOXX\u00ae) during the 2022 mpox outbreak in the US. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.05.16.23289856 (2023).","DOI":"10.1101\/2023.05.16.23289856"},{"key":"6401_CR52","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3201\/eid2203.151158","volume":"22","author":"P Fassbender","year":"2016","unstructured":"Fassbender, P. et al. Generalized cowpox virus infection in a patient with HIV, Germany, 2012. Emerg. Infect. Dis. 22, 553\u2013555 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"6401_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1099\/0022-1317-82-4-855","volume":"82","author":"BP McSharry","year":"2001","unstructured":"McSharry, B. P., Jones, C. J., Skinner, J. W., Kipling, D. & Wilkinson, G. W. G. Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus. J. Gen. Virol. 82, 855\u2013863 (2001).","journal-title":"J. Gen. Virol."},{"key":"6401_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1128\/jvi.40.2.387-395.1981","volume":"40","author":"B Moss","year":"1981","unstructured":"Moss, B., Winters, E. & Cooper, J. A. Deletion of a 9,000-base-pair segment of the vaccinia virus genome that encodes nonessential polypeptides. J. Virol. 40, 387\u2013395 (1981).","journal-title":"J. Virol."},{"key":"6401_CR55","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1099\/vir.0.065664-0","volume":"95","author":"C Maluquer de Motes","year":"2014","unstructured":"Maluquer de Motes, C., Schiffner, T., Sumner, R. P. & Smith, G. L. Vaccinia virus virulence factor N1 can be ubiquitylated on multiple lysine residues. J. Gen. Virol. 95, 2038\u20132049 (2014).","journal-title":"J. Gen. Virol."},{"key":"6401_CR56","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1128\/jvi.69.8.4633-4639.1995","volume":"69","author":"A Alcami","year":"1995","unstructured":"Alcami, A. & Smith, G. L. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69, 4633\u20134639 (1995).","journal-title":"J. Virol."},{"key":"6401_CR57","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1002\/pmic.200700038","volume":"7","author":"CJ Gloeckner","year":"2007","unstructured":"Gloeckner, C. J., Boldt, K., Schumacher, A., Roepman, R. & Ueffing, M. A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7, 4228\u20134234 (2007).","journal-title":"Proteomics"},{"key":"6401_CR58","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1099\/vir.0.81736-0","volume":"87","author":"RA Chen","year":"2006","unstructured":"Chen, R. A., Jacobs, N. & Smith, G. L. Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J. Gen. Virol. 87, 1451\u20131458 (2006).","journal-title":"J. Gen. Virol."},{"key":"6401_CR59","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"6401_CR60","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211\u2013D1217 (2019).","journal-title":"Nucleic Acids Res."},{"key":"6401_CR61","doi-asserted-by":"publisher","first-page":"1027015","DOI":"10.3389\/fmicb.2022.1027015","volume":"13","author":"Y Lu","year":"2022","unstructured":"Lu, Y., Michel, H. A., Wang, P. H. & Smith, G. L. Manipulation of innate immune signaling pathways by SARS-CoV-2 non-structural proteins. Front. Microbiol. 13, 1027015 (2022).","journal-title":"Front. Microbiol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06401-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T20:02:30Z","timestamp":1692820950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06401-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":61,"journal-issue":{"issue":"7975","published-print":{"date-parts":[[2023,8,24]]}},"alternative-id":["6401"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-06401-0","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}